Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2023 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
August 03, 2023 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Continuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the...
June 22, 2023 16:05 ET | Source: Compass Therapeutics

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
June 01, 2023 10:06 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
May 04, 2023 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
April 26, 2023 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
April 19, 2023 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
March 28, 2023 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
March 15, 2023 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Initiated U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC); initial results are expected in the first half of 2024 Initiated...
February 02, 2023 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...